Amyloidosis
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due…
Date: 7th March 2024
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents….
Date: 5th January 2024
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in…
Date: 24th November 2023
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage….
Date: 11th July 2023
ISA 2022: meeting highlights and recent updates in amyloidosis
The 18th Meeting of the International Society of Amyloidosis (ISA) was held in Heidelberg, Germany, on 4-8 September, 2022. This…
Date: 21st October 2022
Myeloma 2022: day one highlights
At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety…
Date: 27th July 2022
Addressing unmet needs and future treatment approaches in AL amyloidosis
Amyloidosis is a heterogeneous disease that results from the deposition of abnormal protein aggregates in various tissues and organs. The…
Date: 1st July 2022
Harnessing the power of immunotherapy in myeloma and amyloidosis
The myeloma treatment landscape has seen a lot of progress in the last few years, with several novel therapies emerging,…
Date: 20th May 2022
Recent advances in amyloidosis treatment
Amyloidosis is a disease that results from the accumulation of a toxic, insoluble protein called amyloid in various tissues and…
Date: 1st April 2022
SOHO 2021: amyloidosis treatment updates
Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of…
Date: 30th September 2021
Post-ASH Amyloidosis Session from VJHemOnc
The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal…
Date: 13th April 2021
Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data
Amyloidosis is the name attributed to a group of diseases caused by the extracellular accumulation of amyloid, an abnormal, insoluble…
Date: 5th February 2021
